Boundless Bio, Inc.
No enriched coverage for $BOLD in the last 7 days.
TANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
TANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
A roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
Recent BOLD coverage spans insider activity, financial news and corporate actions.
In the last 30 days, BOLD insiders filed 9 SEC Form 4 transactions — 9 purchases ($390K) and no sales. The most active reporter was TANG KEVIN with 9 filings.
A 10% owner open-market purchase is a modest bullish signal, but it is not a fundamental catalyst like earnings, guidance, or a deal.
This is an insider open-market purchase disclosed via Form 4, which can modestly support sentiment but is not a fundamental catalyst by itself.
Incremental insider/major-holder buying near the stock’s 52-week high may support momentum positioning.
The filing signals insider accumulation, but it is not a fundamental catalyst like earnings, guidance, or a deal.
Insider/major-holder buying near highs can support sentiment, though it’s not a fundamental re-rating catalyst by itself.
alphai scores every news story that mentions BOLD with an AI model for sentiment and relevance, and aggregates insider trades from Boundless Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
2 min readTANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readTANG KEVIN purchased 57,210 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.48 ($2.46–$2.49, $0.14M total) across 3 trades over 2026-07-06 to 2026-07-08.
2 min readInvesting.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.
6 min readTANG KEVIN purchased 107,463 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.49–$2.54, $0.27M total) across 4 trades over 2026-06-30 to 2026-07-02.
2 min readTANG KEVIN purchased 286,333 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.47–$2.56, $0.71M total) across 6 trades over 2026-06-25 to 2026-06-29.
2 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readBoundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d159021dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: BOUNDLESS BIO, INC.; BOULDER MERGER SUB CORP.; and SERAPHA BIO, INC. Dated as of June 22, 2026 TABLE OF CONTENTS Page Article I. Definitions and Interpretative Provisions 2
4 min readBoundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001782303 false 0001782303 2026-06-15 2026-06-15 0001782303 dei:FormerAddressMember 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da
2 min read
